News

Cells collected from 1st SCD patient receiving gene therapy Lyfgenia

Bluebird Bio has announced it’s completed collecting cells from the first sickle cell disease (SCD) patient receiving the gene therapy Lyfgenia (lovotibeglogene autotemcel), following its recent approval in the U.S. The cells were collected at Children’s National Hospital in Washington D.C., which is part of the company’s…

Oxbryta recommended for NHS coverage to treat sickle cell disease

England’s National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending the country’s National Health Service (NHS) cover Pfizer’s Oxbryta (voxelotor) to treat sickle cell disease. “Today’s approval by NICE marks a significant milestone in sickle cell care, addressing decades of limited access to…